ArticleObesity surgery2026
Simultaneous Versus Interval Sleeve Gastrectomy on Patients Requiring Left Ventricular Assist Devices for End-stage Heart Failure: A Retrospective, Single-Center Cohort Study.
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDurable Left ventricular assist devices (LVADs) are commonly employed as therapy in end-stage heart failure (ESHF). However, individuals with class II obesity (Body Mass Index (BMI) > 35 kg/m²) are often ineligible for heart transplant and have limited options. Laparoscopic sleeve gastrectomy (LSG) is increasingly utilized to facilitate weight loss and improve transplant candidacy. This study evaluates the safety of performing LSG in patients undergoing LVAD implantation who are otherwise ineligible for heart transplantation due to morbid obesity.
methodsA retrospective, single-center cohort study was conducted on congestive heart failure (CHF) patients who underwent either simultaneous LVAD and LSG or staged LSG following LVAD placement. The primary outcome was LSG-related complications within 90 days, including gastrointestinal (GI) bleeding, staple line leaks, and mortality. Secondary outcomes included reoperation rates, acute kidney injury (AKI), transfusion requirements, length of stay (LOS), readmissions, transplant rates, and percent excess body weight loss (%EBWL) at follow-up.
resultsAmong 77 patients (54 simultaneous, 23 interval), LSG-related complications were lower in the simultaneous group (7.4% vs. 17.4%; p = 0.23). Transfusion rates were significantly lower in this group (38.9% vs. 69.6%; p = 0.02), though AKI was more frequent (72.2% vs. 56.6%; p = 0.19). One mortality occurred in the simultaneous cohort. No significant differences were observed in reoperations, LOS, readmissions, transplant rates, or %EBWL.
conclusionSimultaneous LVAD/LSG was associated with comparable sleeve-related complication rates relative to interval LSG. Although limited by small sample size and potential temporal confounding, these findings hypothesize that simultaneous LVAD/LSG may potentially be a feasible strategy in select patients with obesity and ESHF. Larger prospective studies are needed to better define safety, patient selection, and long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.